Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 6: Safety associated with rapid acting antidepressants
Submit an article Journal homepage
7,056
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Can ketamine be a safe option for treatment-resistant bipolar depression?

Balwinder SinghDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7062-8192View further author information
ORCID Icon,
Jennifer L. Vande VoortDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USAView further author information
,
Mark A. FryeDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USAView further author information
&
Simon KungDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USAView further author information
Pages 717-720 | Received 30 Nov 2021, Accepted 18 Feb 2022, Published online: 28 Feb 2022

References

  • Solovitch S. Onetime party drug hailed as miracle for treating severe depression. https://www.washingtonpost.com/national/health-science/a-one-time-party-drug-is-helping-people-with-deep-depression/2016/02/01/d3e73862-b490-11e5-a76a-0b5145e8679a_story.html Accessed 2021 Oct 25. The Washington Post Feb 1. 2016.
  • Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010 Aug;67(8):793–802.
  • Zarate CA Jr., Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012 Jun 1 71(11):939–946.
  • Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017 May;19(3):176–183.
  • Joseph B, Parsaik AK, and Ahmed AT, et al. A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression. J Clin Psychopharmacol. 2021;41(1):71–75.
  • Williams NR, Heifets BD, and Blasey C, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry. 2018 Dec 1;175(12):1205–1215.
  • Singh B, Port JD, Pazdernik V, et al. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: a pilot study. Psychiatry Res Neuroimaging. 2021 Dec 24;320:111432.
  • Zheng W, Zhou YL, Liu WJ, et al. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Disord. 2020 Oct 1;275:38–43.
  • Wilkowska A, Wlodarczyk A, Galuszko-Wegielnik M, et al. Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: an Open-Label Naturalistic Observational Study. Neuropsychiatr Dis Treat. 2021;17:2637–2646.
  • Zhuo C, Ji F, Tian H, et al. Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. Brain Behav. 2020 Aug;10(8):e01674.
  • Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract. 2017 Jun;21(2):99–103.
  • Kantrowitz JT, Halberstam B, and Gangwisch J. Single-Dose Ketamine Followed by Daily D-Cycloserine in Treatment-Resistant Bipolar Depression. J Clin Psychiatry. 2015 Jun;76(6):737–738.
  • Hu Y, Kung S, Ozerdem A, et al. Hypomania Associated with High Dose Ketamine Treatment. Bipolar Disord. 2021;23(4):426–428.
  • Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: a Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 Feb 1 175(2):150–158.
  • Bonaventura J, Lam S, Carlton M, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021 Nov;26(11):6704–6722.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.